Greenleaf Trust Increases Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Greenleaf Trust raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,903 shares of the biopharmaceutical company’s stock after purchasing an additional 63 shares during the quarter. Greenleaf Trust’s holdings in Regeneron Pharmaceuticals were worth $1,671,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $697,296,000. FMR LLC increased its position in shares of Regeneron Pharmaceuticals by 7.3% during the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after acquiring an additional 669,517 shares during the period. International Assets Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals by 76,169.5% during the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock worth $519,148,000 after acquiring an additional 590,314 shares during the period. Moneta Group Investment Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 57,848.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 582,384 shares of the biopharmaceutical company’s stock worth $420,184,000 after acquiring an additional 581,379 shares during the period. Finally, Assenagon Asset Management S.A. increased its holdings in Regeneron Pharmaceuticals by 129.3% in the fourth quarter. Assenagon Asset Management S.A. now owns 216,523 shares of the biopharmaceutical company’s stock valued at $190,170,000 after buying an additional 122,103 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $896.82 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The company has a market capitalization of $98.43 billion, a price-to-earnings ratio of 25.81, a price-to-earnings-growth ratio of 2.59 and a beta of 0.11. The firm has a 50-day simple moving average of $953.01 and a 200-day simple moving average of $891.67. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter in the prior year, the firm earned $10.96 earnings per share. The business’s quarterly revenue was up .6% compared to the same quarter last year. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.8 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on REGN shares. Bank of America increased their target price on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a report on Friday, April 12th. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price on the stock. Truist Financial reissued a “buy” rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Royal Bank of Canada reissued an “outperform” rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $925.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, April 15th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $976.41.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Joseph L. Goldstein sold 2,707 shares of the firm’s stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a total value of $2,571,650.00. Following the completion of the sale, the director now owns 6,382 shares in the company, valued at $6,062,900. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $954.22, for a total value of $95,422.00. Following the completion of the sale, the director now owns 18,382 shares in the company, valued at $17,540,472.04. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Joseph L. Goldstein sold 2,707 shares of the firm’s stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the completion of the sale, the director now owns 6,382 shares of the company’s stock, valued at approximately $6,062,900. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,729 shares of company stock worth $13,124,641. Company insiders own 8.83% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.